BI Asset Management Fondsmaeglerselskab A S Cuts Stock Holdings in Zoetis Inc. $ZTS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

BI Asset Management Fondsmaeglerselskab A S cut its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 31.8% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 192,178 shares of the company's stock after selling 89,537 shares during the period. BI Asset Management Fondsmaeglerselskab A S's holdings in Zoetis were worth $31,642,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Navigoe LLC bought a new stake in shares of Zoetis in the 4th quarter valued at approximately $30,000. Cornerstone Planning Group LLC raised its holdings in Zoetis by 79.3% during the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after buying an additional 88 shares during the period. Migdal Insurance & Financial Holdings Ltd. lifted its position in Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock worth $42,000 after buying an additional 120 shares during the last quarter. Sound Income Strategies LLC lifted its position in Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock worth $46,000 after buying an additional 164 shares during the last quarter. Finally, Bfsg LLC boosted its stake in Zoetis by 614.6% during the first quarter. Bfsg LLC now owns 293 shares of the company's stock worth $48,000 after buying an additional 252 shares during the period. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on ZTS. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Piper Sandler increased their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a research report on Monday, August 11th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Stifel Nicolaus cut Zoetis from a "buy" rating to a "hold" rating and cut their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Finally, UBS Group reduced their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $202.43.

Zoetis Trading Down 0.8%

ZTS traded down $1.2650 on Thursday, reaching $155.4950. 2,411,616 shares of the company traded hands, compared to its average volume of 3,540,633. The company has a market cap of $68.91 billion, a P/E ratio of 26.76, a price-to-earnings-growth ratio of 2.52 and a beta of 0.88. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a one year low of $139.70 and a one year high of $200.33. The firm has a fifty day simple moving average of $154.00 and a two-hundred day simple moving average of $158.75.

Zoetis (NYSE:ZTS - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same period last year, the company posted $1.56 earnings per share. The company's quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Insider Buying and Selling

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.18% of the stock is owned by insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.